加载中
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
常规交易时段
US$17.515
−US$0.635 · -3.50%
盘中时间采用ET。市场数据可能有所延迟。
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
日内区间
当前US$17.515
52周区间
当前US$17.515
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
57
合理估值
情绪
57
多空交织
风险
47
风险偏高
动量
85
强势上行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
日内区间
当前US$17.515
52周区间
当前US$17.515
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|
| 营收 | 649.7万 USD | 148.7万 USD | — | — |
| 毛利 | 649.7万 USD | 148.7万 USD | — | — |
| 研究与开发 | 6745.1万 USD | 4095.4万 USD | 2591.9万 USD | 1430.2万 USD |
| 销售、一般及管理费用 | 1259.8万 USD | 1130.7万 USD | 767.9万 USD | 510.6万 USD |
| 营业费用 | 8118.1万 USD | 5353.7万 USD | 3479.4万 USD | 1976.4万 USD |
| 利息收入 | 1100.9万 USD | 810.3万 USD | 537.7万 USD | 164.7万 USD |
| 折旧和摊销 | 232.9万 USD | 157.5万 USD | 112万 USD | 44.5万 USD |
| 营业利润 | −7468.4万 USD | −5205万 USD | −3479.4万 USD | −1976.4万 USD |
| 净利润 | −6373.1万 USD | −4398万 USD | −2864.1万 USD | −1792.9万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$37.40
上涨空间 113.53%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1516.08万0.00%2.3万亿 USD0.03%US$381.45-0.13%
iShares Russell 2000 ETFIWM1337.99万0.02%787.4亿 USD0.19%US$277.86-0.39%
State Street SPDR S&P Biotech ETFXBI911.17万0.09%98.74亿 USD0.35%US$151.17-1.69%
Vanguard Extended Market ETFVXF561.3万0.01%954亿 USD0.05%US$233.35-0.70%
iShares Russell 2000 Growth ETFIWO328.27万0.02%139.17亿 USD0.24%US$353.63-0.88%
Vanguard Russell 2000 ETFVTWO315.7万0.02%180亿 USD0.06%US$112.24-0.38%
Schwab U.S. Small-Cap ETFSCHA239.74万0.01%218.24亿 USD0.03%US$32.655-0.41%
Truth Social God Bless America ETFYALL116.69万1.42%8216.53万 USD0.65%US$43.365+0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHATruth Social God Bless America ETFYALLAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
